Sugi Predict

Sugi Predict / Compounds / SCHEMBL29569099

SCHEMBL29569099

SCHEMBL29569099

C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(=O)O)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 3/20 0.61
▸ DPP9 Q86TI2 3/20 0.61
▸ DPP8 Q6V1X1 2/20 0.61
▸ CYP1A2 P05177 2/20 0.52
▸ GRM8 O00222 1/20 0.52
▸ GRM6 O15303 1/20 0.52
▸ GRIN2D O15399 1/20 0.52
▸ GRIN3B O60391 1/20 0.52
▸ GSR P00390 1/20 0.52
▸ GRIK1 P39086 1/20 0.52
▸ GRM5 P41594 1/20 0.52
▸ GRIA1 P42261 1/20 0.52
▸ GRIA2 P42262 1/20 0.52
▸ GRIA3 P42263 1/20 0.52
▸ SLC1A3 P43003 1/20 0.52
▸ SLC1A2 P43004 1/20 0.52
▸ SLC1A1 P43005 1/20 0.52
▸ GRIA4 P48058 1/20 0.52
▸ GRIN1 Q05586 1/20 0.52
▸ GRIN2A Q12879 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2807373 1.00 DPP4 (0.61) DPP4DPP9DPP8CYP1A2GRM8
SCHEMBL31031060 1.00 DPP4 (0.61) DPP4DPP9DPP8CYP1A2GRM8
SCHEMBL751142 0.96 DPP4 (0.65) DPP4DPP9DPP8CYP1A2GRM8
SCHEMBL27996817 0.96 DPP4 (0.65) DPP4DPP9DPP8CYP1A2GRM8
SCHEMBL751143 0.96 DPP4 (0.65) DPP4DPP9DPP8CYP1A2GRM8
SCHEMBL29415456 0.96 DPP4 (0.65) DPP4DPP9DPP8CYP1A2GRM8
SCHEMBL29777789 0.92 DPP4 (0.54) DPP4DPP9DPP8CYP1A2GRM8
SCHEMBL9544381 0.92 DPP4 (0.54) DPP4DPP9DPP8CYP1A2GRM8
SCHEMBL9544389 0.92 DPP4 (0.54) DPP4DPP9DPP8CYP1A2GRM8
SCHEMBL29777725 0.91 BACE1 (0.53) DPP4DPP9DPP8CYP1A2GRM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709425-A1 LINKER COMPOUNDS AND LIGAND-DRUG CONJUGATES, PREPARATION METHODS AND USES THEREOF Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (CN) 2026-03-18 — — EP claimed
US-20260027224-A1 ANTIBODY-DRUG CONJUGATES TARGETING CDH3 AND PREPARATION METHODS AND USES THEREOF SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) 2026-01-29 — — US claimed
EP-4674840-A1 CHEMICAL COUPLING LINKER AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2026-01-07 — — EP claimed
EP-4631952-A1 GLUCOCORTICOID RECEPTOR AGONIST AND CONJUGATE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2025-10-15 — — EP claimed
US-20250263437-A1 POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF SICHUAN GOODDOCTOR PANXI PHARMACEUTICAL CO., LTD. (CN) 2025-08-21 — — US claimed
EP-4603487-A1 HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2025-08-20 — — EP claimed
EP-4603109-A1 ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2025-08-20 — — EP claimed
WO-2024235130-A9 POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2025-06-26 — — WO claimed
CN-120202027-A Antibody drug conjugate, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2025-06-24 — — CN claimed
CN-120202203-A Heterocyclic compounds, their preparation and use 四川科伦博泰生物医药股份有限公司 2025-06-24 — — CN claimed
WO-2024114531-A9 HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2024-10-03 — — WO claimed
WO-2024179381-A1 CHEMICAL COUPLING LINKER AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2024-09-06 — — WO claimed
WO-2024149093-A1 GLUCOCORTICOID RECEPTOR AGONIST AND CONJUGATE THEREOF 四川科伦博泰生物医药股份有限公司 2024-07-18 — — WO claimed
WO-2024114531-A1 HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2024-06-06 — — WO claimed
WO-2024114318-A1 DRUG LINKER COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2024-06-06 — — WO claimed
WO-2024114523-A1 ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2024-06-06 — — WO claimed
CN-118105508-A Medicinal linker compound, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2024-05-31 — — CN claimed
EP-4276105-A1 POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd (CN) 2023-11-15 — — EP claimed
CN-114805489-A Polypeptide for repairing skin injury or mucous membrane injury and application thereof 四川好医生攀西药业有限责任公司 2022-07-29 — — CN claimed
WO-2022148289-A1 POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF 四川好医生攀西药业有限责任公司 2022-07-14 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027224-A1 ANTIBODY-DRUG CONJUGATES TARGETING CDH3 AND PREPARATION METHODS AND USES THEREOF H1-3, H1-4, H1-2 DPP4 3447/4885DPP9 3024/4885DPP8 3577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.